Key result
Adjuvant breast cancer therapies, including anthracyclines, radiotherapy, and trastuzumab, are associated with well-documented cardiac toxicity that requires early detection and management.
Why the study?
How can cardiac toxicity due to breast cancer adjuvant therapy be assessed and managed?
How can cardiac toxicity due to breast cancer adjuvant therapy be assessed and managed?
This review highlights the importance of early detection and management of cardiac toxicity in breast cancer survivors receiving adjuvant therapy.
Adjuvant-treated survivors warrant cardiac monitoring; leaves open optimal screening protocols and prevention strategies.
As the number of long-term breast cancer survivors has increased, the side effects of adjuvant cancer therapy, such as cardiac toxicity, remain clinically important. Although the cardiac toxicity due to anthracyclines, radiotherapy, or trastuzumab is well-documented, several issues need to be clarified and are the subjects of extensive ongoing clinical research. This review summarizes the incidence of cardiac toxicity due to breast cancer adjuvant therapy and highlights the current trends in early detection and management of cardiac toxicities.
No takes yet. Share an insight, caveat, or question.
Valachis et al. (2015) conducted a review in Breast cancer. Adjuvant cancer therapy (anthracyclines, radiotherapy, trastuzumab) was evaluated on Cardiac toxicity. Adjuvant breast cancer therapies, including anthracyclines, radiotherapy, and trastuzumab, are associated with well-documented cardiac toxicity that requires early detection and management.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: